INVESTORS & MEDIA
News Release
Regeneron Announces Presentation at the Cowen and Company 29th Annual Healthcare Conference
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.
Source:
Regeneron Pharmaceuticals, Inc.
Investor Relations:
Peter
Dworkin, 914-345-7640
peter.dworkin@regeneron.com
or
Media
Relations:
Laura Lindsay, 914-345-7800
laura.lindsay@regeneron.com
or
Kelly
Hershkowitz, 212-845-5624
khershkowitz@biosector2.com